Skip to main content

Xuhui Bao

Adjunct Professor in the Department of Pathology
Duke Box 3712, Durham, NC 27710
Duke Box 3712, Durham, NC 27710

Selected Publications

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside.

Journal Article Signal Transduct Target Ther · January 8, 2024 Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a pivotal enzyme in lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its related cardiovascular diseases (CVD). This comprehensive review delineates th ... Full text Open Access Link to item Cite

Bacterial‐Mediated Tumor Therapy: Old Treatment in a New Context

Journal Article Advanced Science · April 2023 AbstractTargeted therapy and immunotherapy have brought hopes for precision cancer treatment. However, complex physiological barriers and tumor immunosuppression result in poor efficacy, side effects, and resistance to anti ... Full text Open Access Cite

SETDB1 Restrains Endogenous Retrovirus Expression and Antitumor Immunity during Radiotherapy.

Journal Article Cancer Res · August 3, 2022 UNLABELLED: The type I interferon response plays a pivotal role in promoting antitumor immune activity in response to radiotherapy. The identification of approaches to boost the radiation-induced type I interferon response could help improve the efficacy o ... Full text Link to item Cite

Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death.

Journal Article J Exp Clin Cancer Res · July 15, 2022 Emerging evidence has demonstrated that radiotherapy (RT) can not only cause direct damage to cancer cells but also lead to immunogenic cell death (ICD), which involves the activation of host antitumor immune response in tumor immune microenvironment (TIME ... Full text Link to item Cite


Conference Neuro-Oncology · June 1, 2021 AbstractMyc plays a central role in tumorigenesis by orchestrating the expression of genes essential to numerous cellular processes. While it is well established that Myc functions by binding to its target g ... Full text Cite

ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation.

Journal Article J Clin Invest · February 1, 2021 Novel approaches are needed to boost the efficacy of immune checkpoint blockade (ICB) therapy. Ataxia telangiectasia mutated (ATM) protein plays a central role in sensing DNA double-stranded breaks (DSBs) and coordinating their repair. Recent data indicate ... Full text Link to item Cite

Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer.

Journal Article Nature · December 2020 Despite its success in achieving the long-term survival of 10-30% of treated individuals, immune therapy is still ineffective for most patients with cancer1,2. Many efforts are therefore underway to identify new approaches that enhance such immune 'checkpo ... Full text Link to item Cite

Endogenous Retrovirus Activation as a Key Mechanism of Anti-Tumor Immune Response in Radiotherapy.

Journal Article Radiat Res · April 2020 The generation of DNA double-strand breaks has historically been taught as the mechanism through which radiotherapy kills cancer cells. Recently, radiation-induced cytosolic DNA release and activation of the cGAS/STING pathway, with ensuing induction of in ... Full text Link to item Cite

Limited MOMP, ATM, and their roles in carcinogenesis and cancer treatment.

Journal Article Cell Biosci · 2020 Limited mitochondria outer membrane permeability (MOMP) is a novel biological process where mammalian cells initiate the intrinsic apoptosis pathway with increased mitochondrial permeability but survive. One of the major consequences of limited MOMP is apo ... Full text Link to item Cite

Elevated Risk of Radiation Therapy-Associated Second Malignant Neoplasms in Young African-American Women Survivors of Stage I-IIIA Breast Cancer.

Journal Article Int J Radiat Oncol Biol Phys · October 1, 2019 PURPOSE: To estimate the effect of radiation therapy (RT) on nonbreast second malignant neoplasms (SMNs) in young women survivors of stage I-IIIA breast cancer. METHODS AND MATERIALS: Women aged 20 to 44 years who received a diagnosis of stage I-IIIA breas ... Full text Link to item Cite

Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations.

Journal Article J Immunother Cancer · May 29, 2019 BACKGROUND: D2C7-IT is a novel immunotoxin (IT) targeting wild-type epidermal growth factor receptor (EGFRwt) and mutant EGFR variant III (EGFRvIII) proteins in glioblastoma. In addition to inherent tumoricidal activity, immunotoxins induce secondary immun ... Full text Open Access Link to item Cite

Non-apoptotic Roles of Caspases in Stem Cell Biology, Carcinogenesis, and Radiotherapy

Journal Article Current Stem Cell Reports · March 15, 2019 Purpose of Review: To summarize recent findings on novel roles of caspases in stem cell biology, tumor repopulation, and tissue regeneration. Contrary to the long-held notion that apoptotic caspases are exclusively executioners of programmed cell death, an ... Full text Cite

Efficacy of GLI antagonists in triple-negative inflammatory breast cancer 2D and 3D models

Conference CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION · July 1, 2018 Link to item Cite

XIAP Regulation by MNK Links MAPK and NFκB Signaling to Determine an Aggressive Breast Cancer Phenotype.

Journal Article Cancer Res · April 1, 2018 Hyperactivation of the NFκB pathway is a distinct feature of inflammatory breast cancer (IBC), a highly proliferative and lethal disease. Gene expression studies in IBC patient tissue have linked EGFR (EGFR/HER2)-mediated MAPK signaling to NFκB hyperactivi ... Full text Link to item Cite

Second malignancy in young early-stage breast cancer patients with modern radiotherapy: A long-term population-based study (A STROBE-compliant study).

Journal Article Medicine (Baltimore) · April 2018 Second cancer is a leading cause of death in long-term survivors of younger early-stage breast cancer patients. To date, relationship of age, receipt of radiotherapy (RT), and estimated doses received by target organs have not yet been well elucidated. Usi ... Full text Link to item Cite

Elevated expression of podoplanin and its clinicopathological, prognostic, and therapeutic values in squamous non-small cell lung cancer.

Journal Article Cancer Manag Res · 2018 BACKGROUND: Squamous non-small cell lung cancer (SqNSCLC), as a leading cause of cancer-related deaths worldwide, has limited treatment options and poor prognosis. Thus, novel targeted therapies are desperately needed. MATERIALS AND METHODS: SqNSCLC cases ... Full text Link to item Cite

A combinatorial immunotherapy for malignant brain tumors: D2C7 immunotoxin and immune checkpoint inhibitors.

Conference Journal of Clinical Oncology · March 1, 2017 102 Background: Immunotoxins can induce direct and rapid cytotoxicity by targeting specific tumor antigens. D2C7 is a unique recombinant immunotoxin targeting EGFRwt/EGFRvIII, two frequently overexpressed proteins on gliomas, and ... Full text Cite

Anti-Podoplanin Immunotoxin Therapy For Lung Cancer Treatment